Table 3.

Summary of commercially available imageable beads ³⁸, ⁷³, ⁷⁴.

Feature	LC Bead LUMITM	DC Bead LUMITM	X-Spheres®
Company	BTG	BTG	Interface Biomaterials
Imaging modality	X-ray	X-ray	X-ray
Material	Triiodobenzyl (TIB)-modified acrylamido-polyvinylalcohol-AMPS hydrogel microspheres	TIB-modified acrylamido-polyvinylalcohol-AMPS hydrogel microspheres	TIB-modified acrylic microspheres
Size (μm)	70-150, 100-300	70-150, 100-300	400-600, 600-710, 710-850
Inclusion method	Covalently bounding of iodine moiety (TIB) into the PVA hydrogel structure	Directly coupling of TIB groups to the 1,3-diol units of the beads	Polymerization of methacrylate monomer that contains covalently bound iodine-derivative
Time to market	Cleared by the US FDA in December 2016	CE marked in March 2017	First authorized in 2015
Labeled indication	Hypervascular tumors and arteriovenous malformations (AVMs)	Nonmalignant hypervascular tumors and AVMs

FDA: Food and Drug Administration; CE: Communate Europpene.